Related Experiment Video

Updated: Apr 15, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

3.1K

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B

Malia B Potts1, Elizabeth A McMillan1, Tracy I Rosales1

  • 1Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Nature Chemical Biology
|April 14, 2015
PubMed

Insights

Didemnin B, a natural anticancer drug, induces apoptosis by inhibiting PPT1 and EEF1A1. A genetic biomarker was developed to identify patients likely to respond to this cancer therapy.

Area of Science:

  • Natural Product Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Many cancer treatments derive from natural sources.
  • Didemnin B shows anticancer potential but has limited clinical use due to toxicity and an unclear mechanism.
  • Identifying specific patient responses is crucial for effective cancer therapy.

Purpose of the Study:

  • To elucidate the mechanism of action for didemnin B.
  • To identify a genetic biomarker for predicting patient response to didemnin B.
  • To enhance the therapeutic application of didemnin B in cancer treatment.

Main Methods:

  • Investigated didemnin B's cellular activities through broad-scale screening.
  • Determined didemnin B induces apoptosis via dual inhibition of PPT1 and EEF1A1.
  • Developed a predictive model using genetic data from exceptional responders.

Main Results:

  • Didemnin B selectively triggers rapid apoptosis by inhibiting protein targets PPT1 and EEF1A1.
  • A sparse-feature genetic biomarker was successfully generated to predict didemnin B sensitivity.
  • The biomarker holds potential for patient selection in didemnin B therapy.

Conclusions:

  • Didemnin B's anticancer effect is mediated by dual inhibition of PPT1 and EEF1A1, leading to apoptosis.
  • A novel genetic biomarker can predict patient response, potentially improving didemnin B's therapeutic utility.
  • This research paves the way for personalized cancer treatment strategies using didemnin B.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.4K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.2K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
151
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
186
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197